Please ensure Javascript is enabled for purposes of website accessibility

Editas and Allergan Make Gene-Editing History With First Treatment of Blindness Drug

By Mark Prvulovic - Mar 4, 2020 at 6:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's the first time this type of gene-editing treatment has been tested on a human.

Editas Medicine (EDIT -0.22%) and Allergan (AGN) announced on Wednesday morning that they had just treated the first patient with Editas' flagship drug candidate EDIT-101 as part of the Brilliance phase 1/2 clinical trial. The new experimental gene-editing drug targets a rare eye disorder known as Leber congenital amaurosis (LCA).

What makes this particular treatment noteworthy is that it's the first time a patient's genes are being modified within the body, also known as an in vivo treatmentIn comparison, most gene-editing drugs operate on an ex vivo basis, where targeted cells are removed from the patient first before they are modified and later returned. The trial will be testing 18 LCA patients to see how they respond to EDIT-101, which will be administered via a subretinal injection.

A person snipping out a piece of a DNA strand with scissors.

Image source: Getty Images.

"The first patient dosed in the BRILLIANCE clinical trial marks a significant milestone toward delivering on the promise and potential of CRISPR medicines to durably treat devastating diseases such as LCA10," said Cynthia Collins, CEO and president of Editas.

About the condition

Leber congenital amaurosis is a type of blindness that first occurs in infants. Patients with the condition have mutations of specific genes responsible for the proper development of the retina, the part of the eye that detects light.

There's only one LCA treatment available right now, a pricey drug called Luxturna, which was developed by a now-bought-out biotech company called Spark Therapeutics. However, the drug treats only a specific type of LCA, and it isn't available for most patients with the eye disorder.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$13.47 (-0.22%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.